Back to Search
ALVIN MORGENSTERN, M.D.
M.D.
Specialist
NPI: 1740284132Individual
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
MA 042331(NJ)
Research & Publications (20)
Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model.
PMID 19580472·Radiat Res·2009
8-other
Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates.
PMID 19188157·Clin Cancer Res·2009
7-preclinical
Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. II. Application of the microdosimetric model to experimental results.
PMID 19580473·Radiat Res·2009
8-other
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells.
PMID 19479088·PLoS One·2009
7-preclinical
Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells.
PMID 19139285·Antimicrob Agents Chemother·2009
7-preclinical
Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206.
PMID 18708762·Cancer Biol Ther·2008
8-other
The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy.
PMID 18184988·Phys Med Biol·2008
8-other
Production of 230U/226Th for targeted alpha therapy via proton irradiation of 231Pa.
PMID 18925748·Anal Chem·2008
8-other
Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.
PMID 18347423·Cancer Biol Ther·2008
7-preclinical
Cross-sections of the reaction 232Th(p,3n)230Pa for production of 230U for targeted alpha therapy.
PMID 18374585·Appl Radiat Isot·2008
8-other
Radiofungicidal effects of external gamma radiation and antibody-targeted beta and alpha radiation on Cryptococcus neoformans.
PMID 18378712·Antimicrob Agents Chemother·2008
7-preclinical
Indole-3-carbinol (I3C) exhibits inhibitory and preventive effects on prostate tumors in mice.
PMID 18063461·Food Chem Toxicol·2008
7-preclinical
213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model.
PMID 18483272·Cancer Res·2008
7-preclinical
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
PMID 17891393·Eur J Nucl Med Mol Imaging·2008
7-preclinical
Gemcitabine radiosensitizes multiple myeloma cells to low let, but not high let, irradiation.
PMID 17383762·Radiother Oncol·2007
8-other
Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma.
PMID 17495524·Cancer Biol Ther·2007
3-trial
213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.
PMID 17561973·Cancer Sci·2007
7-preclinical
Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer.
PMID 17582216·Cancer Biol Ther·2007
7-preclinical
213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe.
PMID 17699730·Mol Cancer Ther·2007
8-other
Therapeutic ultrasound facilitates antiangiogenic gene delivery and inhibits prostate tumor growth.
PMID 17699732·Mol Cancer Ther·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 29 E 29TH ST
BAYONNE, NJ 07002 - Phone
- (201) 858-5000
Quick Facts
- NPI
- 1740284132
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile